Scancell Financial Statements From 2010 to 2025
| SCNLF Stock | USD 0.14 0.00 0.00% |
Check Scancell Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scancell Holdings' main balance sheet or income statement drivers, such as , as well as many indicators such as . Scancell financial statements analysis is a perfect complement when working with Scancell Holdings Valuation or Volatility modules.
Scancell |
Scancell Holdings plc Company Return On Equity Analysis
Scancell Holdings' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Scancell Holdings Return On Equity | -0.44 |
Most of Scancell Holdings' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scancell Holdings plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Scancell Holdings plc has a Return On Equity of -0.4427. This is 98.15% lower than that of the Healthcare sector and 98.79% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 42.81% higher than that of the company.
Scancell Holdings plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scancell Holdings's current stock value. Our valuation model uses many indicators to compare Scancell Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scancell Holdings competition to find correlations between indicators driving Scancell Holdings's intrinsic value. More Info.Scancell Holdings plc is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scancell Holdings' earnings, one of the primary drivers of an investment's value.About Scancell Holdings Financial Statements
Scancell Holdings stakeholders use historical fundamental indicators, such as Scancell Holdings' revenue or net income, to determine how well the company is positioned to perform in the future. Although Scancell Holdings investors may analyze each financial statement separately, they are all interrelated. For example, changes in Scancell Holdings' assets and liabilities are reflected in the revenues and expenses on Scancell Holdings' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Scancell Holdings plc. Please read more on our technical analysis and fundamental analysis pages.
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom. Scancell Holdings operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 25 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Scancell Pink Sheet
Scancell Holdings financial ratios help investors to determine whether Scancell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scancell with respect to the benefits of owning Scancell Holdings security.